e-learning
resources
Madrid 2019
Monday, 30.09.2019
Real-world experience of monoclonal antibodies in asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Real life experience with omalizumab and mepolizumab in severe asthma : do patient baseline features preclude effectiveness comparison ?
A. Frix (Liège, Belgium), F. Schleich (Liège, Belgium), V. Paulus (Liège, Belgium), M. Henket (Liège, Belgium), F. Guissard (Liège, Belgium), R. Louis (Liège, Belgium)
Source:
International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Session:
Real-world experience of monoclonal antibodies in asthma
Session type:
Thematic Poster
Number:
2524
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Frix (Liège, Belgium), F. Schleich (Liège, Belgium), V. Paulus (Liège, Belgium), M. Henket (Liège, Belgium), F. Guissard (Liège, Belgium), R. Louis (Liège, Belgium). Real life experience with omalizumab and mepolizumab in severe asthma : do patient baseline features preclude effectiveness comparison ?. 2524
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Real life study showing the epidemiological profile and adherence to treatment of patients with severe allergic asthma in use of omalizumab in the past year.
Source: International Congress 2018 – Biomarkers for evaluating asthma
Year: 2018
Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study
Source: International Congress 2017 – Monitoring asthma control
Year: 2017
Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey
Source: Eur Respir J 2013; 42: 1224-1233
Year: 2013
Long term efficacy and safety of omalizumab in patients with allergic asthma-A real life study
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Omalizumab in severe asthma: real life study
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Physician assessment of asthma control in patients receiving omalizumab in a real-world setting
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012
Patients with asthma and comorbid allergic rhinitis: Is optimal quality of life achievable in real life?
Source: Annual Congress 2011 - Asthma: risk factors and comorbidities
Year: 2011
Which patients should be treated with anti-IgE?
Source: Eur Respir Rev 2007; 16: 85-87
Year: 2007
Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Omalizumab significantly improves quality of life in patients with severe persistent allergic asthma: a pooled analysis
Source: Eur Respir J 2005; 26: Suppl. 49, 49s
Year: 2005
Clinical phenotypes of asthmatics who require long-term use of tiotropium for asthma control: a real-world study
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019
Clinical predictors of the effectiveness of tiotropium in adults with symptomatic asthma: the real-life data
Source: International Congress 2018 – Tests and trends in asthma
Year: 2018
Efficacy and safety of Mepolizumab in a real world severe asthma cohort.
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma
Source: Eur Respir J, 52 (4) 1800936; 10.1183/13993003.00936-2018
Year: 2018
Evaluating the efficacy of omalizumab in severe persistent asthma patients
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
X-Tab: Non-interventional study to assess patient-related mid-term outcomes of omalizumab therapy in severe allergic asthmatic patients
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
The comparative assessment of quality of life in asthma patients treated with inhaled steroids
Source: Eur Respir J 2003; 22: Suppl. 45, 282s
Year: 2003
What patients with IPF can expect concerning symptoms and quality of life during first six months of antifibrotic treatment?
Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept